<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: manufactures", fill: "#7df9ff"},
{source: "3: manufactures", target: "3: broad range", fill: "#7df9ff"},
{source: "3: broad range", target: "3: clinically advanced", fill: "#7df9ff"},
{source: "3: clinically advanced", target: "3: disposable catheters heart assist devices", fill: "#7df9ff"},
{source: "3: disposable catheters heart assist devices", target: "3: cardiac care", fill: "#7df9ff"},
{source: "3: manufactures", target: "9: vascular access catheters", fill: "#e68fac"},
{source: "9: vascular access catheters", target: "9: antiseptic surface", fill: "#e68fac"},
{source: "9: antiseptic surface", target: "9: treatments", fill: "#e68fac"},
{source: "9: vascular access catheters", target: "12: The Company ", fill: "#a1caf1"},
{source: "12: The Company ", target: "12: also sells", fill: "#a1caf1"},
{source: "12: also sells", target: "12: by providing configured kits", fill: "#a1caf1"},
{source: "12: The Company ", target: "20: previously", fill: "#0067a5"},
{source: "20: previously", target: "20: rationalize", fill: "#0067a5"},
{source: "20: rationalize", target: "20: global manufacturing operations", fill: "#0067a5"},
{source: "20: global manufacturing operations", target: "20: manufacturing", fill: "#0067a5"},
{source: "20: manufacturing", target: "20: operations", fill: "#0067a5"},
{source: "20: operations", target: "20: Company ", fill: "#0067a5"},
{source: "20: Company ", target: "20: accelerate", fill: "#0067a5"},
{source: "20: accelerate", target: "20: integration", fill: "#0067a5"},
{source: "20: integration", target: "20: operations into", fill: "#0067a5"},
{source: "20: operations into", target: "20: existing facilities", fill: "#0067a5"},
{source: "20: existing facilities", target: "20: December ", fill: "#0067a5"},
{source: "20: December ", target: "20: San Antonio Texas ", fill: "#0067a5"},
{source: "20: San Antonio Texas ", target: "20: facility", fill: "#0067a5"},
{source: "20: facility", target: "20: formerly been conducted", fill: "#0067a5"},
{source: "20: previously", target: "33: addition as further", fill: "#ff2400"},
{source: "33: addition as further", target: "33: Research and Product Development ", fill: "#ff2400"},
{source: "33: Research and Product Development ", target: "33: nonpulsatile", fill: "#ff2400"},
{source: "33: nonpulsatile", target: "33: centrifugal", fill: "#ff2400"},
{source: "33: addition as further", target: "55: ongoing research", fill: "#ff2400"},
{source: "55: ongoing research", target: "55: development", fill: "#ff2400"},
{source: "55: development", target: "55: effectiveness ease", fill: "#ff2400"},
{source: "55: effectiveness ease", target: "55: reliability", fill: "#ff2400"},
{source: "55: reliability", target: "55: existing products", fill: "#ff2400"},
{source: "55: existing products", target: "55: applications", fill: "#ff2400"},
{source: "55: applications", target: "55: appropriate", fill: "#ff2400"},
{source: "55: ongoing research", target: "112: financial condition", fill: "#9bddff"},
{source: "112: financial condition", target: "112: adverse outcome", fill: "#9bddff"},
{source: "112: adverse outcome", target: "112: actions would materially adversely", fill: "#9bddff"},
{source: "112: actions would materially adversely", target: "112: operations", fill: "#9bddff"},
{source: "112: operations", target: "112: future period cannot", fill: "#9bddff"},
{source: "112: future period cannot", target: "112: predicted with certainty", fill: "#9bddff"},
{source: "112: financial condition", target: "116: regulations", fill: "#c72c48"},
{source: "116: regulations", target: "116: the Company", fill: "#c72c48"},
{source: "116: the Company", target: "116: enforcement", fill: "#c72c48"},
{source: "116: enforcement", target: "116: restrictions", fill: "#c72c48"},
{source: "116: restrictions", target: "116: clearances", fill: "#c72c48"},
{source: "116: clearances", target: "116: Medicaid or Medicare ", fill: "#c72c48"},
{source: "116: regulations", target: "START_HERE", fill: "#c72c48"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Apparel Accessories and Luxury Goods</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Oil and Gas Exploration and Production</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Company">Company</a></td>
      <td>A company, abbreviated as co., is a legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective. Company members share a common purpose and unite to achieve specific, declared goals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Walt_Disney_Company">The Walt Disney Company</a></td>
      <td>The Walt Disney Company, commonly known as Disney (), is an American multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California.\nDisney was originally founded on October 16, 1923, by brothers Walt and Roy O. Disney as the Disney Brothers Cartoon Studio; it also operated under the names the Walt Disney Studio and Walt Disney Productions before changing its name to the Walt Disney Company in 1986.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Pokémon_Company">The Pokémon Company</a></td>
      <td>The Pokémon Company (株式会社ポケモン, Kabushiki gaisha Pokémon) is a Japanese company responsible for brand management, production, publishing, marketing and licensing of the Pokémon franchise, which consists of video game software, a trading card game, anime television series, films, manga, home entertainment products, merchandise, and other ventures. It was established through a joint investment by the three businesses holding the copyright of Pokémon: Nintendo, Game Freak, and Creatures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Weather_Company">The Weather Company</a></td>
      <td>The Weather Company is a weather forecasting and information technology company that owns and operates weather.com and Weather Underground. The Weather Company has been a subsidiary of the Watson &amp; Cloud Platform business unit of IBM since 2016.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Honest_Company">The Honest Company</a></td>
      <td>The Honest Company, Inc. is an American consumer goods company, founded by actress Jessica Alba.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Longaberger_Company">The Longaberger Company</a></td>
      <td>The Longaberger Company is an American manufacturer and distributor of handcrafted maple wood baskets and other home and lifestyle products. The company opened in 1973, was acquired in 2013 by CVSL, Inc., and closed in 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>(<font color="blue">together with</font> its <font color="blue">subsidiaries</font>,  &amp;quote Arrow &amp;quote  or the   &amp;quote Company &amp;quote ) was incorporated as a <font color="blue">Pennsylvania </font><font color="blue">corporation</font> in 1975</td>
    </tr>
    <tr>
      <td>Arrow  develops, <font color="blue"><font color="blue">manufacture</font>s</font> and markets a <font color="blue">broad range</font> of <font color="blue">clinically advanced</font>,  disposable <font color="blue">catheters</font>, heart assist devices and related products for critical and  <font color="blue">cardiac care</font></td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue"><font color="blue">critical care</font> products</font> are <font color="blue">used principally</font> for  <font color="blue">central vascular access</font> in the <font color="blue">administration</font> of fluids, drugs and blood  products, patient monitoring and <font color="blue">diagnostic purposes</font></td>
    </tr>
    <tr>
      <td>These products are used by  anesthesiologists, <font color="blue">critical care</font> specialists, surgeons, cardiologists,  nephrologists, emergency and <font color="blue">trauma physicians</font> and other <font color="blue">health care providers</font></td>
    </tr>
    <tr>
      <td>Arrowapstas <font color="blue">cardiac care</font> products are used by interventional cardiologists, cardiac  surgeons, interventional radiologists and <font color="blue">electrophysiologists</font> for <font color="blue">such purposes</font>  as the <font color="blue">diagnosis</font> and treatment of heart and <font color="blue">vascular disease</font> and to provide  short-term cardiac assist following cardiac surgery, serious heart attack or  <font color="blue">balloon angioplasty</font></td>
    </tr>
    <tr>
      <td>CRITICAL CARE PRODUCTS Arrowapstas <font color="blue"><font color="blue">critical care</font> products</font>, the first of  which were <font color="blue">originally introduced</font> in 1977, accounted for approximately 85dtta0prca of  net sales in each of fiscal 2006, 2005 and 2004</td>
    </tr>
    <tr>
      <td>The majority of these products  are <font color="blue">vascular access <font color="blue">catheters</font></font> and related <font color="blue">devices which consist principally</font> of  the following: the Arrow-Howes(TM) Multi-Lumen Catheter, a catheter equipped  with three or four channels, or lumens, that enables the <font color="blue">simultaneous</font>  <font color="blue">administration</font> of multiple <font color="blue">critical care</font> therapies through a single puncture  site; double-and single-lumen <font color="blue">catheters</font>, which are designed for use in a variety  of clinical procedures; percutaneous sheath introducers, which are used as a  means for <font color="blue">inserting cardiovascular</font> and other <font color="blue">catheterization devices into</font> the  <font color="blue">vascular system</font> during <font color="blue">critical care</font> procedures; radial artery <font color="blue">catheters</font>, which  are used for <font color="blue">measuring arterial blood pressure</font> and taking <font color="blue">blood samples</font>; FlexTip  Plus(TM) epidural <font color="blue">catheters</font>, which are designed to <font color="blue">minimize indwelling</font>  complications <font color="blue">associated with</font> conventional epidural <font color="blue">catheters</font>; Percutaneous  Thrombolytic Devices, which are designed for clearance of thrombosed  <font color="blue">hemodialysis grafts</font> in <font color="blue">chronic hemodialysis patients</font>; and <font color="blue">hemodialysis access</font>  <font color="blue">catheters</font>, including the Cannon CatheterTM, which are used to <font color="blue">facilitate</font>  <font color="blue">dialysis treatment</font></td>
    </tr>
    <tr>
      <td>Many of <font color="blue">the Company</font>apstas <font color="blue">vascular access <font color="blue">catheters</font></font> are treated  with the ARROWg+ard(TM) or ARROWg+ard Blue Plus(TM) <font color="blue">antiseptic surface</font>  <font color="blue">treatments</font> to reduce the risk of catheter related infection</td>
    </tr>
    <tr>
      <td>ARROWg+ard Blue  Plus(TM) is a newer, longer lasting formulation of ARROWg+ard(TM) and provides  <font color="blue">antimicrobial</font> treatment of the <font color="blue">interior lumens</font> and hubs of <font color="blue">each catheter</font></td>
    </tr>
    <tr>
      <td>Many  of <font color="blue">the Company</font>apstas <font color="blue"><font color="blue">procedure kits</font> also</font> feature its <font color="blue">sharps safety devices</font> to  <font color="blue">protect against inadvertent needle sticks</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">also sells</font> its Arrow  Select Kits in certain geographic regions, which serve <font color="blue">the Company</font>apstas customers  <font color="blue">by providing configured kits</font> to meet their specific needs</td>
    </tr>
    <tr>
      <td>These kits can be  <font color="blue">assembled from</font> any of <font color="blue">the Company</font>apstas <font color="blue"><font color="blue">product line</font>s</font> and are <font color="blue">configured according</font>  to a customerapstas specifications</td>
    </tr>
    <tr>
      <td>During the <font color="blue">second quarter</font> of fiscal 2006, as part of its ongoing efforts  to meet physicians &amp;apos  needs for safety and <font color="blue">management</font> of risk of infection in the  <font color="blue">hospital setting</font>, <font color="blue"><font color="blue">the Company</font> </font><font color="blue">began selling</font> its new <font color="blue">Maximal Barrier </font>central  venous access kit, which includes a full body drape, a <font color="blue">catheter treated with</font> the  ARROWg+ard(R) <font color="blue">antimicrobial</font> <font color="blue">technology</font>, and other <font color="blue">accessories</font></td>
    </tr>
    <tr>
      <td>This new kit  <font color="blue">addresses recent guidelines</font> for reducing catheter-related bloodstream infections  <font color="blue">promulgated by</font> the Centers for Disease Control and the Institute for Healthcare  Improvementapstas `100cmam000 Lives &amp;apos  initiative</td>
    </tr>
    <tr>
      <td>In October 2006, the <font color="blue">Company  </font>introduced the Arrow Pressure Injectable PICC (Peripherally Inserted Central  Catheter), <font color="blue">which addresses</font> the <font color="blue">emerging therapeutic</font> needs for a catheter that  can withstand the <font color="blue">higher pressures</font> required by the injection of <font color="blue">contrast media</font>  for CT scans</td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue"><font color="blue">critical care</font> <font color="blue">product line</font> also</font> includes <font color="blue">custom tubing sets</font>  used to connect central venous <font color="blue">catheters</font> to blood pressure monitoring devices  and <font color="blue">drug infusion systems</font>, and the HemoSonic(TM), a <font color="blue">hemodynamic</font> monitoring  system that <font color="blue">continuously</font> measures <font color="blue">descending</font> aortic blood flow using a  non-invasive esophageal ultrasound probe</td>
    </tr>
    <tr>
      <td>In March 2003, <font color="blue"><font color="blue">the Company</font> </font>expanded its <font color="blue"><font color="blue">critical care</font> <font color="blue">product line</font> with</font>  the <font color="blue">acquisition</font> of Klein-Baker Medical, Inc, a company that develops,  <font color="blue"><font color="blue">manufacture</font>s</font> and markets the Neo[heart]Care <font color="blue">product line</font> of specialty <font color="blue">catheters</font>  and related <font color="blue">procedure kits</font> for <font color="blue">use by <font color="blue">neonatal intensive care units</font></font></td>
    </tr>
    <tr>
      <td>As  <font color="blue">previously</font> reported, in <font color="blue">December </font>2004, <font color="blue"><font color="blue">the Company</font> </font>announced a voluntary  <font color="blue">nationwide recall</font> of all of the Neo[heart]Care NeoPICC 1dtta9 FR Peripherally  Inserted Central Catheters (the  &amp;quote NeoPICC Catheters &amp;quote )</td>
    </tr>
    <tr>
      <td>As part of its <font color="blue">previously</font>  announced plans to <font color="blue">rationalize</font> its <font color="blue">global <font color="blue">manufacturing</font> <font color="blue">operations</font></font>, the <font color="blue">Company  </font>decided to <font color="blue">accelerate</font> the <font color="blue">integration</font> of its Neo[heart]Care <font color="blue">manufacturing</font>  <font color="blue">operations</font> into its other <font color="blue">existing <font color="blue">facilities</font></font> and, in <font color="blue">December </font>2005, sold its  San Antonio, Texas <font color="blue">facility</font> where these <font color="blue">operations</font> had <font color="blue">formerly been conducted</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">address <font color="blue">inspectional observations</font></font> <font color="blue">of the US </font>Food and Drug Administration,  or the FDA, and to <font color="blue">facilitate</font> this <font color="blue">integration</font>, in January 2005 the <font color="blue">Company  </font><font color="blue">temporarily ceased</font> the <font color="blue">manufacture</font>, shipment and sale of its entire  Neo[heart]Care <font color="blue">product line</font>, including the NeoPICC Catheters, until it has  completed the <font color="blue">implementation</font> of all <font color="blue">corrective actions</font> related to the FDAapstas  <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>presently expects to submit a new 510(k) pre-market  <font color="blue">notification</font> to the FDA for a <font color="blue">modified version</font> of the NeoPICC Catheter during  the <font color="blue">second quarter</font> of fiscal 2007 and has decided to delay the resumption of  production of the Neo[heart]Care <font color="blue">product line</font>, including the NeoPICC Catheters,  until it has received FDA <font color="blue">marketing clearance</font> for these <font color="blue">modifications</font></td>
    </tr>
    <tr>
      <td>See Notes to Consolidated Financial Statements - Note 19 in Item 8 of  this report and  &amp;quote <font color="blue"><font color="blue">Government </font>Regulation </font>&amp;quote  elsewhere in this Item 1</td>
    </tr>
    <tr>
      <td>CARDIAC CARE PRODUCTS Arrowapstas <font color="blue">cardiac care</font> products accounted for  approximately 15dtta0prca of net sales in each of fiscal 2006, 2005 and 2004</td>
    </tr>
    <tr>
      <td>These  products include cardiac assist products, such as intra-aortic balloon, or IAB,  pumps and <font color="blue">catheters</font>, which are <font color="blue">used primarily</font> to <font color="blue">augment temporarily</font> the pumping  <font color="blue">capability</font> of the heart following cardiac surgery, serious heart attack or  <font color="blue">balloon angioplasty</font></td>
    </tr>
    <tr>
      <td>The Companyapstas IAB products include the AutoCat(TM)2 WAVE  IAB pump and associated LightWAVE(TM) catheter system, which utilizes fiber  optic pressure-sensing catheter instrumentation and <font color="blue">provides total automation</font> of  the <font color="blue">pumping process</font> for the <font color="blue">broadest range</font> of patients, including those with  <font color="blue">severely arrhythmic heartbeats</font></td>
    </tr>
    <tr>
      <td>The AutoCAT(R)2 WAVE(TM) is the only IAB pump  that anticipates <font color="blue">aortic valve closures</font> before they occur and has generated  <font color="blue"><font color="blue">significant</font> interest since</font> its <font color="blue">introduction</font> in January 2004,                                          (3)  <PAGE>    resulting in <font color="blue">customer feedback</font> that has provided <font color="blue"><font color="blue">the Company</font> </font>with valuable  information for making <font color="blue">various <font color="blue">enhancement</font>s</font> to this product</td>
    </tr>
    <tr>
      <td>During the fourth  quarter of fiscal 2006, <font color="blue"><font color="blue">the Company</font> </font>released the <font color="blue">latest version</font> of the  AutoCat(TM)2 WAVE IAB pump and associated LightWAVE(TM) catheter system, which  includes <font color="blue">new software upgrades</font> and related hardware changes, all <font color="blue">contributing</font> to  the <font color="blue">enhanced functionality</font> of the device</td>
    </tr>
    <tr>
      <td>The Companyapstas IAB <font color="blue">products also</font>  include the <font color="blue">Ultraflex </font>7dtta5 Fr</td>
    </tr>
    <tr>
      <td>catheter, which is the smallest IAB in the market  and employs <font color="blue">the Company</font>apstas proprietary, wire reinforced <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">the Company</font>apstas <font color="blue">cardiac care</font> <font color="blue">product line</font> includes  electrophysiology products, which are <font color="blue">used primarily</font> to map the electrical  <font color="blue">signals which activate</font> the heart; the Berman(TM) Angiographic Catheter, which is  used for <font color="blue">pediatric cardiac angiographic procedures</font>; and the Super Arrow-Flex(TM)  sheath, which provides a kink-resistant passageway for the <font color="blue">introduction</font> of  cardiac and other <font color="blue">catheters</font> into the <font color="blue">vascular system</font></td>
    </tr>
    <tr>
      <td>In addition, as further  discussed below under  &amp;quote Research and Product Development, &amp;quote  <font color="blue"><font color="blue">the Company</font> </font>is  currently developing the CorAide(TM) Left Ventricular Assist System, or LVAS, a  small non-pulsatile, <font color="blue">centrifugal</font> flow <font color="blue">ventricular assist</font> device</td>
    </tr>
    <tr>
      <td>SALES AND MARKETING           Arrow markets its products to physicians and <font color="blue">hospitals through</font> a  <font color="blue">combination</font> of direct selling, <font color="blue">independent <font color="blue">distributors</font></font> and group purchasing  <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Within each hospital, marketing efforts are targeted to those  physicians, including <font color="blue">critical care</font> specialists, cardiologists,  anesthesiologists, interventional radiologists, <font color="blue">electrophysiologists</font> and  surgeons, most likely to use <font color="blue">the Company</font>apstas products</td>
    </tr>
    <tr>
      <td>Arrowapstas products are  <font color="blue"><font color="blue">generally</font> sold</font> in the form of pre-sterilized <font color="blue">procedure kits</font> containing the  <font color="blue">catheters</font> and virtually all of the related <font color="blue">medical <font color="blue">components</font></font> and <font color="blue">accessories</font>  needed by the clinician to prepare for and perform the <font color="blue">intended medical</font>  procedure</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">sales revenue</font> is <font color="blue">derived from equipment provided</font> for use  in <font color="blue">connection with certain</font> of <font color="blue">the Company</font>apstas <font color="blue">disposable products</font></td>
    </tr>
    <tr>
      <td>In this market, approximately  94dtta0prca of <font color="blue">the Company</font>apstas fiscal 2006 revenue was <font color="blue">generated by</font> its <font color="blue">direct sales</font>  force</td>
    </tr>
    <tr>
      <td>The remainder resulted <font color="blue">from shipments</font> to <font color="blue">independent <font color="blue">distributors</font></font></td>
    </tr>
    <tr>
      <td>For  the majority of such <font color="blue">distributors</font>, <font color="blue">the Company</font>apstas <font color="blue">products represent</font> a principal  <font color="blue">product line</font></td>
    </tr>
    <tr>
      <td>Direct <font color="blue">selling <font color="blue">generally</font> yields higher</font> gross <font color="blue">profit margins than</font>  sales made through <font color="blue">independent <font color="blue">distributors</font></font></td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">acquisition</font>s of some  of its <font color="blue">distributors</font> in key US and <font color="blue">international</font> markets during the past  several years have resulted in sales and gross profit growth, including, most  recently, its <font color="blue">acquisition</font> in April 2006 of <font color="blue">certain assets</font> of Kimal PLC, its  <font color="blue">former distributor</font> in the United Kingdom and Ireland, <font color="blue">which continues</font> to  distribute <font color="blue">the Company</font>apstas products in the <font color="blue">Middle East </font>region</td>
    </tr>
    <tr>
      <td>Internationally, <font color="blue"><font color="blue">the Company</font> </font>sells its products through <font color="blue">direct sales</font>  <font color="blue">subsidiaries</font> serving markets in Japan, Germany, the Netherlands, France, Spain,  Greece, South Africa, Canada, Mexico, the Czech Republic, Slovakia, Austria,  Switzerland, Portugal, Italy, the United Kingdom and Ireland</td>
    </tr>
    <tr>
      <td><font color="blue">As of October </font>1,  2006, <font color="blue">independent <font color="blue">distributors</font></font> in 91 <font color="blue">additional</font> countries sell <font color="blue">the Company</font>apstas  products in the remainder of the world</td>
    </tr>
    <tr>
      <td>To <font color="blue">support growth</font> in <font color="blue">international</font> sales, <font color="blue"><font color="blue">the Company</font> </font>owns and operates  two <font color="blue">manufacturing</font> <font color="blue">facilities</font> in Chihuahua, Mexico, the second of which was  completed and <font color="blue">commenced production</font> in the <font color="blue">second quarter</font> of fiscal 2006, and has  leased <font color="blue">additional</font> <font color="blue">manufacturing</font> space in Mexico since fiscal 2002</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font> also owns and operates a <font color="blue">manufacturing</font> and product <font color="blue">development</font> <font color="blue">facility</font> in  Hradec Kralove, Czech Republic, which was expanded in fiscal 2003, and a new  <font color="blue">manufacturing</font> and packaging <font color="blue">facility</font> in Zdar, Czech Republic, which was  completed and <font color="blue">commenced production</font> in the <font color="blue">fourth quarter</font> of fiscal 2006</td>
    </tr>
    <tr>
      <td>Both  the new Chihuahua, Mexico plant and the new Zdar, Czech Republic plant were  <font color="blue">constructed as</font> part of <font color="blue">the Company</font>apstas multi-year capital investment plan to  increase its worldwide <font color="blue">manufacturing</font> <font color="blue">capacity</font> and <font color="blue">rationalize</font> its production  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Production </font>is <font color="blue">based primarily on</font> the level of <font color="blue">inventories</font> of finished  products and <font color="blue">projections</font> of <font color="blue">future customer demand with</font> the objective of  <font color="blue">shipping from stock upon receipt</font> of orders</td>
    </tr>
    <tr>
      <td>As <font color="blue">previously</font> reported, increased  demand for <font color="blue">the Company</font>apstas <font color="blue">products over</font> the <font color="blue">last several years</font> had limited its  ability to <font color="blue">supply products at</font> the required unit <font color="blue">volumes given</font> its <font color="blue">previously</font>  existing <font color="blue">manufacturing</font> <font color="blue">capacity</font> level</td>
    </tr>
    <tr>
      <td>As a result, during fiscal 2006, the  Company continued to <font color="blue">actively address</font> the root causes of these <font color="blue">capacity</font>  <font color="blue">constraints</font> that resulted in <font color="blue"><font color="blue">backorders</font> on several products by expanding</font> its  worldwide <font color="blue">manufacturing</font> <font color="blue">capacity</font> and improving the <font color="blue">efficiency</font> of its processes  and <font color="blue"><font color="blue">technology</font> on</font> a <font color="blue">priority basis as</font> part of its <font color="blue">previously</font> reported  &amp;quote Project  Operational Excellence &amp;quote</td>
    </tr>
    <tr>
      <td>As a result of these efforts, <font color="blue"><font color="blue">the Company</font> </font>has been able  to decrease its <font color="blue">backorders</font> and increase its order fill rates during fiscal 2006</td>
    </tr>
    <tr>
      <td>No <font color="blue">single customer accounts</font> for more than 10prca of <font color="blue">the Company</font>apstas sales</td>
    </tr>
    <tr>
      <td>Purchases  of <font color="blue">the Company</font>apstas <font color="blue">products by hospitals</font> and physicians have not <font color="blue">been materially</font>  <font color="blue">influenced by seasonal factors</font></td>
    </tr>
    <tr>
      <td>RESEARCH AND PRODUCT DEVELOPMENT           Arrow is engaged in <font color="blue">ongoing research</font> and <font color="blue">development</font> to introduce  <font color="blue">clinically advanced</font> <font color="blue">new products</font>, to enhance the effectiveness, ease of use,  safety and <font color="blue">re<font color="blue">liability</font></font> of its <font color="blue">existing products</font> and to expand the clinical  <font color="blue"><font color="blue">application</font>s</font> for which use of its products is <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">principal focus</font>  of <font color="blue">the Company</font>apstas research and <font color="blue">development</font> effort is to identify and analyze the  needs of physicians in critical and <font color="blue">cardiac care</font> medicine, and to develop  products that address these needs</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>views <font color="blue">ideas submitted by</font>  physicians and other <font color="blue"><font color="blue">health care <font color="blue">professionals</font></font> as</font> an <font color="blue">important source</font> of  <font color="blue">potential research</font> and <font color="blue">development</font> projects</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes that these  end-users are often in the <font color="blue">best position</font> to conceive of <font color="blue">new products</font> and to  <font color="blue">recommend ways</font> to improve the performance of <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>Many of the  Companyapstas <font color="blue">principal products</font> and <font color="blue">product improvements</font> have resulted from  <font color="blue">collaborative efforts <font color="blue">with physicians</font></font>, other <font color="blue">health care <font color="blue">professionals</font></font> or other  <font color="blue">affiliated entities</font></td>
    </tr>
    <tr>
      <td>For <font color="blue">certain proprietary ideas</font>, <font color="blue"><font color="blue">the Company</font> </font><font color="blue">pays royalties</font>  to <font color="blue">such persons</font>, and in many instances, incorporates <font color="blue">such persons</font> &amp;apos  names in the  trade name or trademark for the <font color="blue">specific product</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">also utilizes</font>  other outside consultants, inventors and <font color="blue">medical <font color="blue">researchers</font></font> to carry on its  research and <font color="blue">development</font> effort and <font color="blue">sponsors research through medical</font>  <font color="blue">associations</font> and <font color="blue">at various universities</font> and <font color="blue">teaching hospitals</font></td>
    </tr>
    <tr>
      <td>Certain of <font color="blue">the Company</font>apstas strategic <font color="blue">acquisition</font>s and <font color="blue">investments</font> have  provided the basis for its <font color="blue">introduction</font> of <font color="blue">significant</font> <font color="blue">new products</font>, including  its IAB pumps and other <font color="blue">cardiac care</font> products, <font color="blue">hemodynamic</font> monitoring device,  Cannon Catheter(TM)                                          (4)  <PAGE>    <font color="blue">hemodialysis catheter product</font> and, until the <font color="blue">temporary cessation</font> of the  Neo[heart]Care(R) <font color="blue">product line</font> in January 2005, specialty <font color="blue">catheters</font> and related  <font color="blue">procedure kits</font> for use in <font color="blue">neonatal intensive care units</font></td>
    </tr>
    <tr>
      <td>Research and <font color="blue">development</font> expenses totaled dlra27dtta5 million (5dtta7prca of net  sales), dlra29dtta7 million (6dtta5prca of net sales) and dlra30dtta4 million (7dtta0prca of net sales)  in fiscal 2006, 2005 and 2004, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Such amounts were used to develop  <font color="blue">new products</font>, improve <font color="blue">existing products</font> and implement <font color="blue">new <font color="blue">technology</font></font> to produce  these products</td>
    </tr>
    <tr>
      <td>There can be no assurance that the FDA or any similar <font color="blue">foreign <font color="blue">government</font></font>  <font color="blue"><font color="blue">regulatory</font> authority will grant</font> <font color="blue"><font color="blue">the Company</font> </font><font color="blue">authorization</font> to <font color="blue">market products</font>  under <font color="blue">development</font> or, if such <font color="blue">authorization</font> is obtained, that <font color="blue">such products will</font>  <font color="blue">prove <font color="blue">competitive</font></font> when <font color="blue">measured against</font> other <font color="blue">available products</font></td>
    </tr>
    <tr>
      <td>The Companyapstas  principal long-term <font color="blue">development</font> programs are described below</td>
    </tr>
    <tr>
      <td>HEMOSONIC During fiscal 2006, <font color="blue"><font color="blue">the Company</font> </font>continued to support its  HemoSonicTM <font color="blue">cardiac output monitoring system</font> that <font color="blue">continuously</font> measures  <font color="blue">descending</font> aortic blood flow using a non-invasive esophageal ultrasound probe</td>
    </tr>
    <tr>
      <td>The Companyapstas fiscal 2006 sales of this product were <font color="blue">primarily outside</font> of the  US <font color="blue">The Company </font>is continuing its <font color="blue">development</font> of a <font color="blue">second generation version</font> of  the device that will have a more extensive feature set, which the <font color="blue">Company  </font>believes will be more user-friendly and <font color="blue">better able</font> to meet the needs of a  <font color="blue">broader range</font> of <font color="blue">clinicians</font></td>
    </tr>
    <tr>
      <td>CORAIDE LVAS In April 2001, <font color="blue"><font color="blue">the Company</font> </font><font color="blue">entered into</font> an <font color="blue">agreement</font> with  The Cleveland Clinic Foundation, or the CCF, for the <font color="blue">exclusive license</font> of the  CCFapstas patents in the field of non-pulsatile, <font color="blue">centrifugal</font> flow <font color="blue">ventricular assist</font>  devices for the treatment of <font color="blue">congestive heart failure</font> and a related <font color="blue">agreement</font>  for <font color="blue">continued research</font> and <font color="blue">development</font> of the CorAide(TM) <font color="blue">ventricular assist</font>  device that had been a joint <font color="blue">development</font> effort of the CCF and the National  Institutes of Health</td>
    </tr>
    <tr>
      <td>The unique, magnetically suspended continuous flow pumping  mechanism of the CorAide(TM) device uses moving blood as its <font color="blue">lubricating system</font></td>
    </tr>
    <tr>
      <td>Arrow considers the CorAide to be one of the most promising, continuous flow  bridge-to-transplant devices currently in <font color="blue">development</font> and believes it may  represent a <font color="blue">future generation</font> of permanent <font color="blue">ventricular assist</font> devices if human  organ <font color="blue">systems prove</font> to be adaptable to non-pulsatile blood flow over a long  period of time</td>
    </tr>
    <tr>
      <td>During fiscal 2006, <font color="blue"><font color="blue">the Company</font> </font>continued its <font color="blue">previously</font> reported  European clinical trial of the CorAide(TM) left <font color="blue">ventricular assist</font> system, or  LVAS During the third quarter of fiscal 2006, the <font color="blue">researchers</font> conducting this  clinical trial identified the need for several <font color="blue">modifications</font> to the CorAide(TM)  device</td>
    </tr>
    <tr>
      <td>As a result, <font color="blue"><font color="blue">the Company</font> </font>decided not to <font color="blue">proceed with</font> the <font color="blue">enrollment</font> of  <font color="blue"><font color="blue">additional</font> patients</font> in the <font color="blue">trial until</font> these design <font color="blue">modifications</font> have been  assessed and implemented</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>views the CorAide(TM) LVAS as a long-term <font color="blue">development</font>  program</td>
    </tr>
    <tr>
      <td>The <font color="blue">current version</font> of the CorAide(TM) device is intended to provide  support for <font color="blue">Class IV </font><font color="blue">congestive heart failure</font> patients waiting for heart  transplantation, candidates for bridging to <font color="blue">natural recovery</font> of ventricular  function and patients requiring longer-term support</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes that  the CorAide(TM)apstas smaller size, less invasive surgical approach and <font color="blue">inherently</font>  <font color="blue">simpler design promises better opportunities</font> for <font color="blue">broader <font color="blue">market acceptance</font> than</font>  <font color="blue">currently marketed</font> LVAS devices</td>
    </tr>
    <tr>
      <td>MANUFACTURING AND PRODUCTION TECHNOLOGY           Arrow has developed the <font color="blue">core technologies</font> that <font color="blue"><font color="blue">the Company</font> </font>believes are  <font color="blue">necessary</font> for it to design, develop and <font color="blue">manufacture</font> complex, <font color="blue">high quality</font>  catheter-related <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">technological</font> <font color="blue">capability</font> has enabled the  Company to develop <font color="blue">internally</font> many of the <font color="blue">major <font color="blue">components</font></font> of its products and  reduce its unit <font color="blue">manufacturing</font> costs</td>
    </tr>
    <tr>
      <td>To help further reduce <font color="blue">manufacturing</font> costs  and improve <font color="blue">efficiency</font>, <font color="blue"><font color="blue">the Company</font> </font>has <font color="blue">increasingly automated</font> the production of  its high-volume products and plans to continue to make <font color="blue"><font color="blue">significant</font> capital</font>  <font color="blue">expenditures</font> to improve <font color="blue">efficiency</font> and reduce operating costs</td>
    </tr>
    <tr>
      <td>Raw materials and <font color="blue"><font color="blue">purchased <font color="blue">components</font></font> essential</font> to Arrowapstas business have  <font color="blue">typically been available within</font> the <font color="blue">lead times</font> required by <font color="blue"><font color="blue">the Company</font> </font>and,  <font color="blue">consequently</font>, <font color="blue">procurement</font> has not <font color="blue">historically</font> posed any <font color="blue">significant</font> problems in  the operation of <font color="blue">the Company</font>apstas business</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>currently maintains single  suppliers for certain of its out-sourced <font color="blue">components</font>, particularly those used in  the AutoCAT(R)2WAVETM, for reasons of quality assurance, sole source  <font color="blue">availability</font>, cost-effectiveness or <font color="blue">constraints</font> resulting from <font color="blue">regulatory</font>  <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Arrow works <font color="blue">closely with</font> its suppliers to <font color="blue">assure continuity</font> of  <font color="blue">supply while</font> maintaining <font color="blue">high quality</font> and <font color="blue">re<font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>See  &amp;quote <font color="blue">Supply Interruption </font>&amp;quote   in Item 1A of this report</td>
    </tr>
    <tr>
      <td>As <font color="blue">previously</font> reported, in April 2004, <font color="blue">the Company</font>apstas Board of Directors  authorized the <font color="blue">initiation</font> of a multi-year capital investment plan to increase  its worldwide <font color="blue">manufacturing</font> <font color="blue">capacity</font> and <font color="blue">rationalize</font> its production <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>This effort included the <font color="blue">construction</font> or <font color="blue">acquisition</font> of <font color="blue">additional</font> <font color="blue">manufacturing</font>  <font color="blue">facilities</font> in Zdar, Czech Republic and in Chihuahua, Mexico, both of which new  <font color="blue">facilities</font> were completed and commenced <font color="blue">operations</font> during fiscal 2006, and the  <font color="blue">installation</font> of related new equipment, which is ongoing</td>
    </tr>
    <tr>
      <td>PATENTS, TRADEMARKS, PROPRIETARY RIGHTS AND LICENSES           Arrow believes that patents and other <font color="blue">proprietary rights</font> are important to  its business</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also relies upon trade secrets, know-how, continuing  <font color="blue"><font color="blue">technological</font> innovations</font> and <font color="blue">licensing opportunities</font> to develop and maintain  its <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>Arrow currently holds numerous US and foreign  patents and patent <font color="blue"><font color="blue">application</font>s</font> that relate to aspects of the <font color="blue"><font color="blue">technology</font> used</font> in  certain of <font color="blue">the Company</font>apstas products, including its <font color="blue">radial artery catheter</font>,  percutaneous sheath introducer, hemodialysis catheter, percutaneous thrombolytic  device, <font color="blue">interventional diagnostic sheath</font> and <font color="blue">catheter products</font>, CorAide(TM)  LVAS, <font color="blue">esophageal ultrasound probe jacket</font> and IAB <font color="blue">pump products</font></td>
    </tr>
    <tr>
      <td>In addition, Arrow is a party to several license <font color="blue">agreement</font>s with  <font color="blue">unrelated third parties pursuant</font> to which it has obtained, <font color="blue">under varying terms</font>,  the <font color="blue">exclusive rights</font> to <font color="blue">certain patents</font> held <font color="blue">by such third parties</font> in  <font color="blue">consideration</font> for <font color="blue">royalty payments</font></td>
    </tr>
    <tr>
      <td>Many of <font color="blue">the Company</font>apstas <font color="blue">major products</font>,  including its <font color="blue">antiseptic surface</font> treatment for <font color="blue">catheters</font>, have been developed  pursuant to such license <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>All <font color="blue">existing patents</font> owned by or licensed  to <font color="blue"><font color="blue">the Company</font> </font>relating to any of its <font color="blue">major products</font> expire after fiscal 2007</td>
    </tr>
    <tr>
      <td>(5)  <PAGE>           There can be no assurance that patent <font color="blue"><font color="blue">application</font>s</font> owned by or licensed  to <font color="blue"><font color="blue">the Company</font> </font>will result in the issuance of patents or that any patents owned  by or licensed to <font color="blue"><font color="blue">the Company</font> </font><font color="blue">will provide <font color="blue">competitive</font> advantages</font> for the  Companyapstas products or will not be challenged or <font color="blue">circumvented by others</font></td>
    </tr>
    <tr>
      <td>See   &amp;quote <font color="blue">Dependence </font>on <font color="blue">Patents and Proprietary Rights </font>&amp;quote  in Item 1A of this report</td>
    </tr>
    <tr>
      <td>From time to time, <font color="blue"><font color="blue">the Company</font> </font>is subject to <font color="blue">legal actions involving</font>  patent and other <font color="blue"><font color="blue">intellectual</font> property</font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>had been a <font color="blue">defendant</font>  in a lawsuit in the <font color="blue"><font color="blue">United States</font> </font>District Court in the Southern District of New  York, in which the plaintiffs, Thierry Pourchez and Bard Access Systems Inc,  alleged that <font color="blue">the Company</font>apstas Cannon-Cath(TM) split-tip hemodialysis <font color="blue">catheters</font>,  which were acquired as part of <font color="blue">the Company</font>apstas <font color="blue">acquisition</font> in November 2002 of  <font color="blue">specified assets</font> of Diatek, Inc, infringed a patent owned by or licensed to the  plaintiffs</td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2003, this lawsuit was <font color="blue">stayed pending</font> the US Patent  and Trademark Officeapstas ruling on its re-examination of the <font color="blue"><font color="blue">patent at</font> issue</font></td>
    </tr>
    <tr>
      <td>In  September 2005, the Court dismissed this lawsuit because the US Patent and  <font color="blue">Trademark Office </font>had not yet concluded its re-examination of the <font color="blue">patent at</font>  issue</td>
    </tr>
    <tr>
      <td>The <font color="blue">plaintiffs may seek reinstatement</font> of this lawsuit when the  re-examination is concluded, which is expected to occur in calendar 2006,  although <font color="blue"><font color="blue">the Company</font> </font><font color="blue">cannot presently predict</font> the <font color="blue">precise timing</font></td>
    </tr>
    <tr>
      <td>Based on  information <font color="blue">presently available</font> to <font color="blue">the Company</font>, <font color="blue"><font color="blue">the Company</font> </font>believes that its  products do not infringe any valid claim of the plaintiffs &amp;apos  patent and that,  <font color="blue">consequently</font>, it has <font color="blue">meritorious legal defenses <font color="blue">with respect</font></font> to this action in  the event it were to be reinstated</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is currently a plaintiff in two related <font color="blue">patent <font color="blue">infringement</font></font>  lawsuits in the <font color="blue"><font color="blue">United States</font> </font>District Court in Baltimore, Maryland against  <font color="blue"><font color="blue">Datascope </font>Corp</font></td>
    </tr>
    <tr>
      <td>of Montvale, New Jersey</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue"><font color="blue">manufacture</font>s</font> and sells the  Arrow-Trerotola(TM) Percutaneous Thrombolytic Device (PTD(R)), which is used to  mechanically declot native arterio-venous fistulae and <font color="blue">synthetic hemodialysis</font>  grafts</td>
    </tr>
    <tr>
      <td>The PTD was <font color="blue">invented by</font> Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Scott Trerotola </font>while working at Johns  Hopkins University</td>
    </tr>
    <tr>
      <td>Johns Hopkins University, the owner of <font color="blue">three patents</font>  covering the PTD, is also a plaintiff, and <font color="blue"><font color="blue">the Company</font> </font>is the <font color="blue">exclusive license</font>e  of the Trerotola patents</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has alleged that <font color="blue">Datascope </font>infringes these  <font color="blue">three patents</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">also commenced</font> a <font color="blue">patent <font color="blue">infringement</font></font> lawsuit in the United  States District Court in Boston, Massachusetts against <font color="blue">Spire Corporation </font>of  Bedford, Massachusetts</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is the owner of <font color="blue"><font color="blue">United States</font> </font>Patent Nodtta  6cmam872cmam198, which covers a method of inserting a double-Y-shaped multi-lumen  catheter</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has alleged that the use of Spireapstas Pourchez RetrO(TM)  High Flow Kink-Resistant Catheter infringes this patent</td>
    </tr>
    <tr>
      <td>This case is currently  in the middle of the <font color="blue">discovery phase</font>, and a trial is anticipated <font color="blue">during calendar</font>  year 2007, although <font color="blue"><font color="blue">the Company</font> </font><font color="blue">cannot presently predict</font> the <font color="blue">precise timing</font></td>
    </tr>
    <tr>
      <td>Although the ultimate outcome of any of these actions is not expected to  have a material adverse effect on <font color="blue">the Company</font>apstas business or <font color="blue">financial condition</font>,  whether an <font color="blue">adverse outcome</font> in any of these <font color="blue">actions would materially <font color="blue">adversely</font></font>  affect <font color="blue">the Company</font>apstas reported results of <font color="blue">operations</font> in any <font color="blue">future period cannot</font>  be <font color="blue">predicted with certainty</font></td>
    </tr>
    <tr>
      <td>Arrow owns a number of <font color="blue">registered <font color="blue">trademarks</font></font> in the <font color="blue"><font color="blue">United States</font> </font>and, in  addition, has obtained <font color="blue">registration</font> in many of its <font color="blue">major foreign markets</font> for the  trademark ARROW(R) and certain other <font color="blue">trademarks</font></td>
    </tr>
    <tr>
      <td>GOVERNMENT REGULATION           As a developer, <font color="blue"><font color="blue">manufacture</font>r</font> and marketer of <font color="blue">medical devices</font>, Arrow is  subject to extensive regulation by, among other <font color="blue"><font color="blue">government</font>al entities</font>, the FDA  and the <font color="blue">corresponding</font> state, local and foreign <font color="blue">regulatory</font> agencies in  <font color="blue"><font color="blue">jurisdiction</font>s</font> in which <font color="blue"><font color="blue">the Company</font> </font>sells its products</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">regulations</font> govern</font>  the <font color="blue">introduction</font>, marketing, <font color="blue">distribution</font>, <font color="blue">installation</font> and servicing of medical  devices, the observance of <font color="blue">certain standards <font color="blue">with respect</font></font> to the <font color="blue">manufacture</font>,  testing and labeling of <font color="blue">such devices</font>, the maintenance of <font color="blue">certain records</font>, the  tracking of <font color="blue">such devices</font> and other matters</td>
    </tr>
    <tr>
      <td>Failure to comply with applicable  federal, state, local or <font color="blue">foreign laws</font> or <font color="blue">regulations</font> could subject the <font color="blue">Company  </font>to <font color="blue">enforcement</font> action, including product seizures, recalls, operating  <font color="blue">restrictions</font>, withdrawal of <font color="blue">marketing clearance</font>s or approvals, and civil and  criminal penalties, including exclusion under Medicaid or Medicare, any one or  more of which could have a material adverse effect on <font color="blue">the Company</font></td>
    </tr>
    <tr>
      <td>In recent  years, the FDA has pursued a more rigorous <font color="blue">enforcement</font> program to ensure that  <font color="blue">regulated businesses</font>, like <font color="blue">the Company</font>apstas, <font color="blue">comply with applicable laws</font> and  <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The FDA, in <font color="blue">cooperation</font> with US Customs and Border Protection, or  CBP, <font color="blue">also administers controls over</font> the import of <font color="blue"><font color="blue">medical devices</font> into</font> the US  The CBP imposes its own <font color="blue">regulatory</font> <font color="blue">requirements</font> on the import of <font color="blue">the Company</font>apstas  products, including inspection and <font color="blue">possible sanctions</font> for <font color="blue">noncompliance</font></td>
    </tr>
    <tr>
      <td>In  addition, the FDA <font color="blue">administers certain controls over</font> the export of medical  <font color="blue">devices from</font> the US See  &amp;quote Stringent <font color="blue"><font color="blue">Government </font>Regulation </font>&amp;quote  in Item 1A of this  report</td>
    </tr>
    <tr>
      <td>In addition, federal, state, local and <font color="blue">foreign laws</font> and <font color="blue">regulations</font>  regarding the <font color="blue">manufacture</font> and sale of <font color="blue">medical devices</font> are subject to future  changes</td>
    </tr>
    <tr>
      <td>There can be no assurance that such changes or FDA, state, local or  foreign <font color="blue">regulatory</font> agency <font color="blue">enforcement</font> activities will not have a material  adverse effect on <font color="blue">the Company</font>apstas business, <font color="blue">financial condition</font> or results of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In October 2002, The Medical Device User Fee and Modernization Act of  2002 was enacted, which amended the FDAapstas <font color="blue">regulations</font> to provide, among other  things, the ability for the FDA to impose user fees for pre-market reviews of  <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">filings with</font> the FDA for pre-market review are  subject to this fee structure</td>
    </tr>
    <tr>
      <td>The <font color="blue">precise amount</font> of fees that <font color="blue"><font color="blue">the Company</font> </font>will  <font color="blue">incur each year will</font> be <font color="blue">dependent upon</font> the <font color="blue">specific quantity</font> and nature of its  filings</td>
    </tr>
    <tr>
      <td>Through the Medical Device User Fee and Modernization Act of 2002, the  FDA increased its oversight of <font color="blue">businesses involved with</font> the <font color="blue">reprocessing</font> of  single use <font color="blue">medical devices</font>, or SUDs</td>
    </tr>
    <tr>
      <td>The regulation was amended to require  <font color="blue">reprocessing</font> labeling, clarify submission pathways and define the <font color="blue">requirements</font>  for <font color="blue">validation</font> of cleaning, sterilizing and <font color="blue">functional performance</font> of  reprocessed SUDs</td>
    </tr>
    <tr>
      <td>The <font color="blue">improved guidance</font> to reprocessors <font color="blue">facilitate</font>s the  <font color="blue">reprocessing</font> business and may result in <font color="blue">increased competition</font> and <font color="blue">price erosion</font></td>
    </tr>
    <tr>
      <td>On occasion, <font color="blue"><font color="blue">the Company</font> </font>has received <font color="blue">notification</font>s, including warning  letters, from the FDA of alleged <font color="blue">deficiencies</font> in <font color="blue">the Company</font>apstas <font color="blue">compliance with</font>  FDA <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>In addition, from time to time <font color="blue"><font color="blue">the Company</font> </font>has recalled, or  issued <font color="blue">safety alert</font>s on, certain of its products, including its <font color="blue">voluntary recall</font>  in <font color="blue">December </font>2004 of its NeoPICC Catheters</td>
    </tr>
    <tr>
      <td>(6)  <PAGE>             In fiscal 2005, <font color="blue"><font color="blue">the Company</font> </font>received three warning <font color="blue">letters from</font> the FDA  related to the FDAapstas prior <font color="blue">inspections</font> of <font color="blue">the Company</font>apstas Mount Holly, New Jersey  <font color="blue">facility</font>, where it <font color="blue"><font color="blue">manufacture</font>s</font> the Arrow Trerotola PTD(TM) Percutaneous  Thrombolytic Device (the  &amp;quote PTD &amp;quote ), and its Reading, <font color="blue">Pennsylvania </font><font color="blue">facility</font> with  respect to oversight of its Neo[heart]Care <font color="blue">manufacturing</font> <font color="blue">operations</font> and its San  Antonio, Texas <font color="blue">facility</font> where it formerly <font color="blue">manufacture</font>d Neo[heart]Careapstas NeoPICC  Catheters prior to its <font color="blue">termination</font> of <font color="blue">operations</font> at this <font color="blue">facility</font> and  <font color="blue">integration</font> of such <font color="blue">operations</font> into other <font color="blue">existing <font color="blue">facilities</font></font></td>
    </tr>
    <tr>
      <td>The letters  referred to <font color="blue">inspectional observations</font> that the FDA had <font color="blue">previously</font> issued  <font color="blue">concerning</font> the PTDapstas and Neo[heart]Careapstas non-conformance with certain Quality  System Regulations for <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>responded to the warning  <font color="blue">letters by describing</font> the specific follow-on <font color="blue">corrective actions</font> it had taken,  including, as <font color="blue">previously</font> reported, the <font color="blue">temporary cessation</font> of the <font color="blue">manufacture</font>  and sale of its entire Neo[heart]Care <font color="blue">product line</font> and, <font color="blue">with respect</font> to the PTD,  the <font color="blue">implementation</font> and <font color="blue">enhancement</font> of new compliance procedures, as well as  related <font color="blue">additional</font> training of operation personnel</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">Company  </font>reiterated its <font color="blue">commitment</font> to enhancing its good <font color="blue">manufacturing</font> practices and  <font color="blue">quality systems</font></td>
    </tr>
    <tr>
      <td>As part of its <font color="blue">Project Operational Excellence </font>program, in <font color="blue">February </font>2005  <font color="blue"><font color="blue">the Company</font> </font>engaged Quintiles Consulting, a provider of global consulting  services to the medical device, <font color="blue">pharmaceutical</font> and <font color="blue">biologics industries</font>, to  assist its project teams in <font color="blue"><font color="blue">implementing</font> rigorous compliance procedures</font> that in  many respects are expected to exceed those meeting existing <font color="blue">regulatory</font>  <font color="blue">requirements</font>, with the objective of achieving the <font color="blue">highest practicable levels</font> of  <font color="blue"><font color="blue">product quality</font> assurance</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>continued its progress during fiscal 2006  in <font color="blue">implementing</font> these <font color="blue">enhanced compliance procedures</font>, and expects this process  to be completed during the <font color="blue">first quarter</font> of fiscal 2007, after which the <font color="blue">Company  </font>will embed these <font color="blue">procedures into</font> its <font color="blue">corporate culture as</font> part of its ongoing  <font color="blue">commitment</font> to maintaining <font color="blue">high quality</font> standards</td>
    </tr>
    <tr>
      <td>To date, no FDA warning letter, recall or <font color="blue">safety alert</font> has had a material  adverse effect on <font color="blue">the Company</font>, but there can be no assurance that any such event  would not have such an effect in the future</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has <font color="blue">also increasingly become</font> subject to new FDA and state  <font color="blue"><font color="blue">regulations</font> govern</font>ing the <font color="blue">distribution</font> of <font color="blue">pharmaceutical</font>s because some of its  <font color="blue">procedure kits</font> contain small quantities of certain <font color="blue">prescription</font> drugs  <font color="blue">manufacture</font>d by others, such as Lidocaine, to assist the physician in performing  the <font color="blue">intended medical</font> procedure</td>
    </tr>
    <tr>
      <td>These new <font color="blue">regulations</font>, which vary somewhat  <font color="blue">depending on</font> the <font color="blue">jurisdiction</font> and are still evolving, impose rigorous compliance  <font color="blue">requirements</font> <font color="blue">with respect</font> to <font color="blue">both licensing</font> of <font color="blue">distributors</font> and provision of  <font color="blue">drug pedigree certificates confirming</font> the <font color="blue">authenticity</font> of the <font color="blue">pharmaceutical</font>s  being <font color="blue">distributed</font>, including those contained in <font color="blue">the Company</font>apstas kits</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font> is in the process of obtaining licenses and <font color="blue">implementing</font> other procedures for  <font color="blue">compliance with</font> these new <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>In addition, the delivery of <font color="blue">the Company</font>apstas products is <font color="blue">also regulated by</font>  the <font color="blue">US Department of Health and Human Services </font>and comparable state and  foreign agencies responsible for <font color="blue">reimbursement</font> and regulation of healthcare</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is <font color="blue">also <font color="blue">governed by</font> federal</font>, state, local and <font color="blue">foreign laws</font>  of general applicability, such as those <font color="blue">regulating employee health</font> and safety</td>
    </tr>
    <tr>
      <td>In the early to mid 1990s, the review time by the FDA to approve medical  devices for commercial release lengthened, and the number of marketing  <font color="blue">clearances</font> and <font color="blue">approvals decreased</font></td>
    </tr>
    <tr>
      <td>In response to public and <font color="blue">congressional</font>  concern, the <font color="blue">FDA Modernization Act </font>of 1997 was adopted with the intent of  bringing better <font color="blue">definition</font> to the <font color="blue">clearance process</font> for <font color="blue">new <font color="blue">medical products</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">While FDA </font><font color="blue">review times</font> have <font color="blue">improved since passage</font> of the 1997 Act, there can be  no assurance that the FDA <font color="blue">review process will</font> not continue to delay the  Companyapstas <font color="blue">introduction</font> of <font color="blue">new products</font> in the US in the future</td>
    </tr>
    <tr>
      <td>In addition,  many <font color="blue">foreign countries</font> have adopted more stringent <font color="blue">regulatory</font> <font color="blue">requirements</font> that  also have added to the delays and <font color="blue">uncertainties <font color="blue">associated with</font></font> the release of  <font color="blue">new products</font>, as well as the clinical and <font color="blue">regulatory</font> costs of <font color="blue">supporting such</font>  releases</td>
    </tr>
    <tr>
      <td>It is possible that delays in receipt of, or failure to receive, any  <font color="blue">necessary</font> clearance or approval for <font color="blue">the Company</font>apstas <font color="blue">new product offerings could</font>  have a material adverse effect on <font color="blue">the Company</font>apstas business, <font color="blue">financial condition</font> or  results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>HEALTH CARE COST CONTAINMENT AND THIRD PARTY REIMBURSEMENT           <font color="blue">Government </font>and private sector initiatives to limit the growth of health  care costs, including <font color="blue">price regulation</font>, <font color="blue">competitive</font> pricing, insurance coverage  and payment policies, and managed-care <font color="blue">arrangements</font>, are continuing in the  <font color="blue"><font color="blue">United States</font> </font>and in many other countries where <font color="blue"><font color="blue">the Company</font> </font>does business</td>
    </tr>
    <tr>
      <td>As a  result of these changes, the marketplace has placed <font color="blue">increased emphasis on</font> the  delivery of more cost-effective medical therapies</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>programs,  including Medicare and Medicaid, <font color="blue">private health care insurance</font> and managed-care  plans have attempted to <font color="blue">control costs by limiting</font> the amount of <font color="blue">reimbursement</font>  <font color="blue">such third party payors will pay</font> to hospitals, other <font color="blue">medical institutions</font> and  physicians for particular products, procedures or <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>The increased  <font color="blue">emphasis on health care cost containment may</font> result in <font color="blue">reduced growth</font> in demand  for certain of <font color="blue">the Company</font>apstas products in markets in the US where Arrow has 80prca  or <font color="blue">greater market</font> share, and protecting that market share has affected the  Companyapstas pricing in some instances</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">also continues</font> to <font color="blue">face pricing</font>  pressures in certain <font color="blue"><font color="blue">product line</font>s</font> in both <font color="blue">European and Japanese </font><font color="blue">markets as</font>  <font color="blue"><font color="blue">government</font>s strive</font> to <font color="blue">curtail increases</font> in <font color="blue">health care costs</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font> anticipates that the US Congress, state legislatures, <font color="blue">foreign <font color="blue">government</font></font>s and  the private sector <font color="blue">will continue</font> to review and <font color="blue">assess <font color="blue">alternative</font> health care</font>  delivery and <font color="blue">payment systems</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot predict</font> what <font color="blue">additional</font>  <font color="blue">legislation</font> or regulation, if any, relating to the <font color="blue"><font color="blue">health care industry</font> may</font> be  enacted in the future or what impact the adoption of any federal, state or  <font color="blue">foreign health care</font> reform, private sector reform or <font color="blue">market forces may</font> have on  its business</td>
    </tr>
    <tr>
      <td>There can be no assurance that any <font color="blue">such reforms will</font> not have a  material adverse effect on <font color="blue">the Company</font>apstas business, <font color="blue">financial condition</font> or  results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>COMPETITION           Arrow faces substantial <font color="blue">competition from</font> a number of other companies in  the market for <font color="blue">catheters</font> and related <font color="blue">medical devices</font> and equipment, ranging from  small, start-up enterprises to companies that are <font color="blue">larger than</font> Arrow with greater  financial and other resources</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes that  its products are <font color="blue">competing primarily on</font> the basis of <font color="blue">product quality</font> and  performance, product features that <font color="blue">provide enhanced benefits</font> to patients,  customer and sales support, and cost-effectiveness</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also believes  that its comprehensive <font color="blue">manufacturing</font> <font color="blue">capability</font> enables it to expedite the  <font color="blue">development</font> and market <font color="blue">introduction</font> of <font color="blue">new products</font> and product features, and to  reduce <font color="blue">manufacturing</font> costs, thereby permitting it to respond more <font color="blue">effectively</font> to  <font color="blue">competitive</font> pricing in an <font color="blue">environment</font> where its ability to <font color="blue">increase prices</font> is  limited</td>
    </tr>
    <tr>
      <td>ENVIRONMENTAL COMPLIANCE           <font color="blue">The Company </font>is subject to <font color="blue">various federal</font>, state and <font color="blue">local laws</font> and  <font color="blue">regulations</font> relating to the protection of the <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>In the course of its  business, <font color="blue"><font color="blue">the Company</font> </font>is involved in the handling, storing and disposal of  <font color="blue">materials which</font> are <font color="blue">classified as hazardous</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes that its <font color="blue">operations</font> comply in all material respects  with applicable <font color="blue">environment</font>al laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Although the <font color="blue">Company  </font>continues to make any <font color="blue">necessary</font> capital and operational <font color="blue">expenditures</font> for  protection of the <font color="blue">environment</font>, it does not anticipate that these <font color="blue">expenditures</font>  will have a material adverse effect on its business, <font color="blue">financial condition</font> or  results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>PRODUCT LIABILITY AND INSURANCE           The design, <font color="blue">manufacture</font> and marketing of <font color="blue">medical devices</font> of the types  produced by <font color="blue"><font color="blue">the Company</font> </font>entail an <font color="blue">inherent risk</font> of <font color="blue">product <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>The  Companyapstas products are used in surgical and <font color="blue">intensive care settings with</font>  <font color="blue">seriously ill patients</font></td>
    </tr>
    <tr>
      <td>Although <font color="blue"><font color="blue">the Company</font> </font>believes that, <font color="blue">based on</font> claims made  against <font color="blue"><font color="blue">the Company</font> </font>in the past, the amount of <font color="blue">product <font color="blue">liability</font></font> insurance  maintained by <font color="blue"><font color="blue">the Company</font> </font>is adequate, there can be no assurance that such  insurance will be available, or in an amount sufficient to satisfy claims made  against <font color="blue"><font color="blue">the Company</font> </font>in the future, or that <font color="blue"><font color="blue">the Company</font> </font>will be able to obtain  insurance in the future at satisfactory rates or in <font color="blue">adequate amounts</font></td>
    </tr>
    <tr>
      <td>The  Companyapstas primary global <font color="blue">product <font color="blue">liability</font></font> insurance policy is on a claims made  basis</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims in the future, regardless of their ultimate  outcome, could result in <font color="blue">costly <font color="blue">litigation</font></font> and could have a material adverse  effect on <font color="blue">the Company</font>apstas business, reputation, its ability to attract and retain  customers for its products, and its results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>EMPLOYEES           <font color="blue">As of October </font>1, 2006, <font color="blue"><font color="blue">the Company</font> </font>had approximately 4cmam000 full-time  employees, of which 279 were hourly-paid <font color="blue">manufacturing</font> employees at the  Companyapstas Reading and Wyomissing, <font color="blue">Pennsylvania </font><font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font> has never experienced an organized work stoppage or strike and considers its  <font color="blue">relations with</font> its employees to be good</td>
    </tr>
    <tr>
      <td>AVAILABLE INFORMATION           Arrowapstas <font color="blue">internet address</font> is: http://www</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>makes  available, free of charge, on its <font color="blue">internet website</font> its annual reports on Form  10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other  information filed or furnished pursuant to the Securities Exchange Act of 1934,  as amended, or the Exchange Act, as soon as reasonably practicable after these  filings have been made electronically with the SEC The Companyapstas Code of  Conduct, which applies to all of its directors, officers and other employees, is  also posted on its website</td>
    </tr>
    <tr>
      <td>Information <font color="blue">contained on</font> <font color="blue">the Company</font>apstas website is  not <font color="blue">incorporated by reference</font> in this report</td>
    </tr>
    <tr>
      <td>In particular, <font color="blue"><font color="blue">the Company</font> </font>must obtain specific clearance or  approval from the FDA before it can market <font color="blue">new products</font> or <font color="blue">certain modified</font>  products in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, <font color="blue">permission</font> to distribute a  new device <font color="blue">generally</font> can be met either through a 510(k) premarket <font color="blue">notification</font>  or an <font color="blue">application</font> for a premarket approval, or PMA           Under the FDAapstas <font color="blue">requirements</font>, if a <font color="blue"><font color="blue">manufacture</font>r</font> can establish that a  newly developed device is  &amp;quote substantially equivalent &amp;quote  to a legally marketed  predicate device, the <font color="blue"><font color="blue">manufacture</font>r</font> may seek <font color="blue">marketing clearance</font> from the FDA to  market the device by filing a 510(k) premarket <font color="blue">notification</font> with the FDA With  the exception of one IAB product, <font color="blue"><font color="blue">the Company</font> </font>has, to date, obtained FDA  <font color="blue">marketing clearance</font> for its <font color="blue"><font color="blue">products on</font>ly through</font> the 510(k) premarket  <font color="blue">notification</font> process</td>
    </tr>
    <tr>
      <td>The 510(k) premarket <font color="blue">notification</font> must be                                          (8)  <PAGE>    <font color="blue">supported by data establishing</font> the claim of substantial equivalence to the  satisfaction of the FDA The process of obtaining a 510(k) clearance is normally  three months or less</td>
    </tr>
    <tr>
      <td>If substantial <font color="blue">equivalence cannot</font> be established or if the FDA determines  that <font color="blue">additional</font> safety and effectiveness data is required to support an  approval, the FDA will require that the <font color="blue"><font color="blue">manufacture</font>r</font> submit a PMA <font color="blue">application</font>  that must be <font color="blue">approved by</font> the FDA prior to marketing the device in the United  States</td>
    </tr>
    <tr>
      <td>The PMA <font color="blue">application</font> must be supported by extensive data, including  preclinical (laboratory) data and <font color="blue">human clinical data</font>, to <font color="blue">demonstrate</font> the safety  and efficacy of the device <font color="blue">with respect</font> to its intended use disclosed in the  <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>Certain of <font color="blue">the Company</font>apstas products, including the IAB and IAB pump and  CorAideTM <font color="blue">ventricular assist</font> device currently under <font color="blue">development</font>, require  approval through the more rigorous PMA <font color="blue">application</font> process</td>
    </tr>
    <tr>
      <td>By regulation, the  FDA has 180 days to review a PMA <font color="blue">application</font> and during that time an advisory  <font color="blue">committee may evaluate</font> the <font color="blue">application</font> and <font color="blue">provide recommendations</font> to the FDA  While the FDA has approved PMA <font color="blue"><font color="blue">application</font>s</font> within the allotted time period,  review more often occurs over a <font color="blue">significant</font>ly protracted period, usually 18 to  36 months, and some devices may never be approved for marketing</td>
    </tr>
    <tr>
      <td>There can be no assurance that the FDA will grant all such  <font color="blue">clearances</font> or approvals sought by <font color="blue"><font color="blue">the Company</font> </font>or that FDA review will not  <font color="blue">involve delays <font color="blue">adversely</font> affecting</font> the marketing and sale of its products</td>
    </tr>
    <tr>
      <td>Both  a 510(k) premarket <font color="blue">notification</font> <font color="blue">and a PMA </font><font color="blue">application</font>, if approved, may also  include <font color="blue">significant</font> limitations on the indicated uses for which a product may be  marketed</td>
    </tr>
    <tr>
      <td>FDA <font color="blue">enforcement</font> policy prohibits the promotion of <font color="blue">approved medical</font>  devices for unapproved uses</td>
    </tr>
    <tr>
      <td>In addition, product approvals can be withdrawn for  failure to comply with <font color="blue">regulatory</font> <font color="blue">requirements</font> or the occurrence of unforeseen  problems following initial marketing</td>
    </tr>
    <tr>
      <td>The FDA often requires post-market surveillance <font color="blue">requirements</font> for  <font color="blue">significant</font> risk devices, such as <font color="blue">ventricular assist</font> devices, that require  <font color="blue">ongoing collection</font> of clinical data during commercialization, which must be  gathered, analyzed and submitted to the FDA <font color="blue">periodically</font> for up to several  years</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is also required to adhere to applicable US and  <font color="blue">international</font> quality system <font color="blue">regulations</font>, which require that the <font color="blue">Company  </font><font color="blue">manufacture</font> its products and maintain its records in a prescribed manner with  respect to design, test, and <font color="blue">manufacturing</font> and quality control activities</td>
    </tr>
    <tr>
      <td>To  the extent that any quality issues are identified <font color="blue">with respect</font> to <font color="blue">the Company</font>apstas  products, <font color="blue"><font color="blue">the Company</font> </font>could be subject to substantial costs and write-offs,  which could materially impact its results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, the  Company is required to comply with FDA <font color="blue">requirements</font> for labeling and promotion  of its products</td>
    </tr>
    <tr>
      <td>Medical device laws are also in effect in many of the <font color="blue">countries outside</font>  the US in which <font color="blue"><font color="blue">the Company</font> </font>does business</td>
    </tr>
    <tr>
      <td>These laws range from comprehensive  device approval and quality system <font color="blue">requirements</font> for some or all of <font color="blue">the Company</font>apstas  products to simpler requests for product data, certifications or <font color="blue">compliance with</font>  packaging or labeling <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Many of the <font color="blue">regulations</font> applicable to the  Companyapstas products in <font color="blue">foreign countries</font> are similar to those of the FDA and the  number, scope and stringency of these <font color="blue">requirements</font> are increasing, which is  adding to the delays and <font color="blue">uncertainties <font color="blue">associated with</font></font> new product releases, as  well as the clinical and <font color="blue">regulatory</font> costs of <font color="blue">supporting such</font> releases</td>
    </tr>
    <tr>
      <td>For  example, in the European Union, a single <font color="blue">regulatory</font> approval process has been  created, with approval represented by the CE-mark</td>
    </tr>
    <tr>
      <td>Although <font color="blue"><font color="blue">the Company</font> </font>has to  date received <font color="blue">authorization</font> to CE-mark many of its more innovative products,  including its Cannon Catheter(TM), there can be no assurance that its other  products under <font color="blue">development</font> will be able to meet this stringent requirement for  marketing a medical device in the European Union</td>
    </tr>
    <tr>
      <td>The regulation of medical  devices in Japan is <font color="blue">governed by</font> the Pharmaceutical Affairs Law, or the PAL  Under the PAL, medical device <font color="blue"><font color="blue">manufacture</font>r</font>s outside of Japan, such as the  Company, must appoint a Marketing Authorization Holder, or MAH, located in Japan  that holds a license to import and sell <font color="blue">medical devices</font>, and provide primary  <font color="blue">distribution</font> services, including <font color="blue">conducting quality assurance</font> and safety control  tasks for each such device</td>
    </tr>
    <tr>
      <td>The PAL was amended in July 2006 to require foreign  <font color="blue">manufacturing</font> <font color="blue">facility</font> accreditation by the MAH and also to permit the Japanese  Government, through the Ministry of Health, Labor and Welfare, to inspect  foreign <font color="blue">manufacturing</font> <font color="blue">facilities</font> that produce <font color="blue">medical devices</font> that are imported  into Japan</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is in the process of completing product documentation  files and other procedures for <font color="blue">compliance with</font> the amended PAL In addition, the  Company is required to notify the FDA if it exports to certain countries medical  devices <font color="blue">manufacture</font>d in the US that have not <font color="blue">been cleared by</font> the FDA for  <font color="blue">distribution</font> in the US           Failure to comply with applicable federal, state, local or <font color="blue">foreign laws</font>  or <font color="blue">regulations</font> could subject <font color="blue"><font color="blue">the Company</font> </font>to <font color="blue">enforcement</font> action, including  product seizures, recalls, operating <font color="blue">restrictions</font>, withdrawal of marketing  <font color="blue">clearances</font> or approvals or other required licenses, prohibition against  importation of products from <font color="blue">manufacturing</font> <font color="blue">facilities</font> outside the US, and  civil and criminal penalties, including exclusion under Medicaid or Medicare,  any one or more of which could have a material adverse effect on its business,  <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Federal, state, local and foreign  laws and <font color="blue">regulations</font> regarding the <font color="blue">development</font>, <font color="blue">manufacture</font> and sale of medical  devices are subject to future changes</td>
    </tr>
    <tr>
      <td>There can be no assurance that such  changes will not have a material adverse effect on <font color="blue">the Company</font>apstas business,  <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Significant Competition and Continual Technological Change           The markets for <font color="blue">medical devices</font> are highly <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font> currently competes with many companies in the <font color="blue">development</font> and marketing of  <font color="blue">catheters</font> and related <font color="blue">medical devices</font>, as well as for establishing <font color="blue">relationships</font>  with academic and research institutes, <font color="blue"><font color="blue">intellectual</font> property</font> licenses and  collaborative <font color="blue">development</font> <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Some of <font color="blue">the Company</font>apstas <font color="blue">competitors</font> have  access to <font color="blue">greater financial</font> and other <font color="blue">resources than</font> it does</td>
    </tr>
    <tr>
      <td>Furthermore, the markets for <font color="blue">medical devices</font> are <font color="blue">characterized</font> by rapid  product <font color="blue">development</font> and <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>Technological <font color="blue">advances by one</font> or  more of <font color="blue">the Company</font>apstas current or future <font color="blue">competitors</font> could render its present or  future products obsolete or uneconomical</td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">future success will</font>  <font color="blue">depend upon</font> its ability to develop <font color="blue">new products</font> and <font color="blue">technology</font> to remain  <font color="blue">competitive</font> with other <font color="blue">developers</font> of <font color="blue">catheters</font> and related <font color="blue">medical devices</font>, as  well as to address the <font color="blue">increasingly sophisticated</font> and varied needs of its  <font color="blue">prospective consumers</font></td>
    </tr>
    <tr>
      <td>The Companyapstas business <font color="blue">strategy emphasizes</font> the continued  <font color="blue">development</font> and commercialization of <font color="blue">new products</font> and the <font color="blue">enhancement</font> of  <font color="blue">existing products</font> for the <font color="blue">critical care</font> and <font color="blue">cardiac care</font>                                          (9)  <PAGE>    markets</td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue"><font color="blue">the Company</font> </font>will be able to continue to  <font color="blue">successfully</font> develop <font color="blue">new products</font> and to enhance <font color="blue">existing products</font>, to  <font color="blue">manufacture</font> these products in a <font color="blue">commercially viable manner</font>, to obtain required  <font color="blue">regulatory</font> approvals or to gain satisfactory <font color="blue">market acceptance</font> for its products</td>
    </tr>
    <tr>
      <td>Health Care Cost Containment and Third Party Reimbursement           The Companyapstas products are purchased principally by hospitals, hospital  networks and <font color="blue">hospital buying groups</font></td>
    </tr>
    <tr>
      <td>Although its products are <font color="blue">used primarily</font>  for non-optional medical procedures, <font color="blue"><font color="blue">the Company</font> </font>believes that the overall,  <font color="blue">escalating cost</font> of <font color="blue">medical products</font> and services has led and <font color="blue">will continue</font> to  lead to <font color="blue">increased pressures upon</font> the <font color="blue">health care industry</font> to reduce the cost or  usage of <font color="blue">certain products</font> and services</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, these cost  pressures have led to <font color="blue">increased emphasis on</font> the price and cost-effectiveness of  any <font color="blue">treatment regimen</font> and medical device</td>
    </tr>
    <tr>
      <td>Third party payors, such as  <font color="blue">government</font>al programs (eg, Medicare and Medicaid), <font color="blue">private insurance</font> plans and  <font color="blue">managed care</font> plans, which are <font color="blue">billed by hospitals</font> for <font color="blue">such health care services</font>,  are <font color="blue">increasingly negotiating</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and  services and may deny <font color="blue">reimbursement</font> if they determine that a device was not used  in accordance with cost-effective treatment methods as determined by the payor,  was experimental, un<font color="blue">necessary</font> or used for an <font color="blue">unapproved indication</font></td>
    </tr>
    <tr>
      <td>As a result,  even though a new medical device may have been <font color="blue">approved by</font> the FDA, the <font color="blue">Company  </font>may find limited demand for the device until <font color="blue">reimbursement</font> approval has been  obtained <font color="blue">from <font color="blue">government</font>al</font> and <font color="blue">private third party payors</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">reimbursement</font> for  <font color="blue">the Company</font>apstas products is not available or at an insufficient level, the <font color="blue">Company  </font>would not be able to sell its <font color="blue">products on</font> a <font color="blue">competitive</font> basis</td>
    </tr>
    <tr>
      <td>Many <font color="blue">international</font> markets have <font color="blue"><font color="blue">government</font> managed health care systems</font>  that control <font color="blue">reimbursement</font> for certain <font color="blue">medical devices</font> and procedures and, in  most such markets, there also are <font color="blue">private insurance</font> systems which impose similar  <font color="blue">cost restraints</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">hospital purchasing decisions</font> or  <font color="blue">government</font> or private third party <font color="blue">reimbursement</font> policies in the <font color="blue"><font color="blue">United States</font> </font>or  in <font color="blue">international</font> markets will not <font color="blue">adversely</font> affect the <font color="blue">profitability</font> of the  Companyapstas products</td>
    </tr>
    <tr>
      <td>Several <font color="blue">comprehensive health care reform proposals</font> have been, and  continue to be, considered by the US Congress</td>
    </tr>
    <tr>
      <td>While none of these proposals  have to <font color="blue">date been adopted</font>, the intent of these proposals was, <font color="blue">generally</font>, to  expand health care coverage for the uninsured and reduce the rate of growth of  total health care <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>In addition, certain states have made  <font color="blue">significant</font> changes to their Medicaid programs and have <font color="blue">adopted various measures</font>  to <font color="blue">expand coverage</font> and <font color="blue">limit costs</font></td>
    </tr>
    <tr>
      <td>Several <font color="blue">foreign countries</font> in which the  Company does business are also considering, and in some countries have already  adopted, similar reforms to limit the growth of <font color="blue">health care costs</font>, including  <font color="blue">price regulation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Implementation </font>of <font color="blue">government</font> health care reform, and other  efforts to <font color="blue">control costs may limit</font> the price of, or the <font color="blue">level at which</font>  <font color="blue">reimbursement</font> is provided for, <font color="blue">the Company</font>apstas products</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>anticipates  that the US Congress, state legislatures, <font color="blue">foreign <font color="blue">government</font></font>s and the private  sector <font color="blue">will continue</font> to review and <font color="blue">assess <font color="blue">alternative</font> health care</font> delivery and  <font color="blue">payment systems</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot predict</font> what <font color="blue">additional</font> <font color="blue">legislation</font> or  regulation, if any, relating to the <font color="blue"><font color="blue">health care industry</font> may</font> be enacted in the  future or what impact the adoption of any federal, state or <font color="blue">foreign health care</font>  reform, private sector reform or <font color="blue">market forces may</font> have on its business</td>
    </tr>
    <tr>
      <td>There  can be no assurance that any <font color="blue">such reforms will</font> not have a material adverse  effect on <font color="blue">the Company</font>apstas business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Consolidation within the Medical Device Industry           In keeping with the <font color="blue">increased emphasis on</font> cost-effectiveness in health  care delivery, the current trend among hospitals and other customers of medical  device <font color="blue"><font color="blue">manufacture</font>r</font>s is to <font color="blue">consolidate into larger purchasing groups</font> to enhance  <font color="blue">purchasing power</font></td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">transactions</font> with customers tend to be larger,  more complex and involve more long-term contracts than in the past</td>
    </tr>
    <tr>
      <td>If the  Company is not one of the <font color="blue">providers selected by</font> a purchasing group, it may be  <font color="blue">precluded from</font> making sales to members of the purchasing group</td>
    </tr>
    <tr>
      <td>Even if the  Company is one of the <font color="blue">selected providers</font>, it may be at a disadvantage relative  to other <font color="blue">selected providers</font> that are able to offer volume discounts <font color="blue">based on</font>  purchases of a <font color="blue">broader range</font> of medical equipment and supplies</td>
    </tr>
    <tr>
      <td>Furthermore, the  enhanced <font color="blue">purchasing power</font> of these larger customers may also increase the  pressure on pricing of <font color="blue">the Company</font>apstas products and <font color="blue"><font color="blue">the Company</font> </font>may be required to  commit to a <font color="blue">pricing level</font> that has a material adverse effect on its sales and  profit margins, business, <font color="blue">financial condition</font> and results of operation</td>
    </tr>
    <tr>
      <td>The medical device industry has also experienced some <font color="blue">consolidation</font>,  partly in order to offer a <font color="blue">broader range</font> of products to large purchasers</td>
    </tr>
    <tr>
      <td>As  these <font color="blue">consolidation</font>s occur, competition to provide products like <font color="blue">the Company</font>apstas  will become more intense</td>
    </tr>
    <tr>
      <td>To the extent that <font color="blue"><font color="blue">the Company</font> </font>is forced to reduce its  prices, its business will become less profitable unless it is able to achieve  <font color="blue">corresponding</font> reductions in its expenses</td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>on <font color="blue">Patents and Proprietary Rights </font>          <font color="blue">The Company </font>owns numerous US and foreign patents and has several US  and foreign patent <font color="blue"><font color="blue">application</font>s</font> pending</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also has <font color="blue">exclusive license</font>  rights to <font color="blue">certain patents</font> held <font color="blue">by third parties</font></td>
    </tr>
    <tr>
      <td>These patents relate to aspects  of the <font color="blue"><font color="blue">technology</font> used</font> in certain of <font color="blue">the Company</font>apstas products</td>
    </tr>
    <tr>
      <td>In addition,  certain of <font color="blue">the Company</font>apstas patents are due to expire within the <font color="blue">next two years</font>,  including a US patent related to the <font color="blue">original formulation</font> of its ARROWg+ard(R)  <font color="blue">antiseptic surface</font> treatment</td>
    </tr>
    <tr>
      <td>The number of units sold in the US with the  <font color="blue">original formulation</font> of the ARROWg+ard(R) <font color="blue">antiseptic surface</font> treatment as a  percentage of <font color="blue">the Company</font>apstas total US multilumen and hemodialysis unit sales  was 18prca in fiscal 2006</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, <font color="blue"><font color="blue">the Company</font> </font>has <font color="blue">been converting</font> many of  its sales of ARROWg+ard(R) coated products from the <font color="blue">original formulation</font> to the  newer, longer lasting ARROWg+ard(R) BluePlus formulation and believes that this  transition will reduce the potential risk <font color="blue">associated with</font> the expiration of the  patent related to the original ARROWg+ard(R) formulation</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may be  unsuccessful in its efforts to <font color="blue">extend patent protection through improvement</font>  patents or <font color="blue">modifications</font>, and the failure to maintain its patents could have a  material adverse effect on <font color="blue">the Company</font></td>
    </tr>
    <tr>
      <td>In addition, there can be no assurance  that pending patent <font color="blue"><font color="blue">application</font>s</font> will result in issued patents or that patents  issued to or licensed-in by <font color="blue"><font color="blue">the Company</font> </font>will not be challenged or circumvented  by <font color="blue">competitors</font> or found to be valid or sufficiently broad to protect its  <font color="blue">technology</font> or to provide it with any <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also  <font color="blue">relies on</font> trade secrets and proprietary <font color="blue">technology</font> that it seeks to protect, in  part, through confidentiality <font color="blue">agreement</font>s with employees, consultants and other  parties</td>
    </tr>
    <tr>
      <td>There can be no assurance that                                          (10)  <PAGE>    these <font color="blue">agreement</font>s will not be breached, that <font color="blue"><font color="blue">the Company</font> </font>will have adequate  remedies for any breach, that <font color="blue">others will</font> not <font color="blue">independently</font> develop  substantially equivalent proprietary information or that <font color="blue">third parties will</font> not  otherwise gain access to its trade secrets</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>expends <font color="blue">significant</font>  resources to monitor and enforce its <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>However, it  may not be able to detect <font color="blue">infringement</font> and its <font color="blue"><font color="blue">competitive</font> position</font> in the  <font color="blue">industry could</font> be materially <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>There has been substantial <font color="blue">litigation</font> regarding patent and other  <font color="blue"><font color="blue">intellectual</font> property</font> rights in the medical device industry</td>
    </tr>
    <tr>
      <td>From time to time,  <font color="blue"><font color="blue">the Company</font> </font>is subject to <font color="blue">legal actions involving</font> patent and other <font color="blue">intellectual</font>  property claims</td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font><font color="blue">litigation</font> against <font color="blue"><font color="blue">the Company</font> </font>regarding its patents  or <font color="blue">infringement</font> of the <font color="blue">patent rights</font> of <font color="blue">others could</font> have a material adverse  effect on its business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Historically, <font color="blue">litigation</font> has also been <font color="blue">necessary</font> to enforce and <font color="blue">defend certain</font>  patent and <font color="blue">trademark rights</font> held by <font color="blue">the Company</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">litigation</font> may be  <font color="blue">necessary</font> to <font color="blue">enforce patent</font> and other <font color="blue"><font color="blue">intellectual</font> property</font> rights belonging to  <font color="blue">the Company</font>, to protect its trade secrets or other know-how owned by it, or to  <font color="blue">defend itself against</font> claimed <font color="blue">infringement</font> of the rights of others and to  determine the scope and validity of its and others &amp;apos  <font color="blue">proprietary rights</font></td>
    </tr>
    <tr>
      <td>Any such  <font color="blue">litigation</font> could result in substantial cost to and diversion of <font color="blue">effort by</font> the  Company</td>
    </tr>
    <tr>
      <td>Adverse de<font color="blue">termination</font>s in any such <font color="blue">litigation</font> could subject the <font color="blue">Company  </font>to <font color="blue">significant</font> <font color="blue">liabilities</font> to third parties, require it to seek licenses from  third parties for <font color="blue">significant</font> royalties or prevent it from <font color="blue">manufacturing</font>,  selling or using certain of its products, any one or more of which could have a  material adverse effect on <font color="blue">the Company</font>apstas business, <font color="blue">financial condition</font> and  results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Associated </font>with International Operations           Because <font color="blue"><font color="blue">the Company</font> </font>generates <font color="blue">significant</font> sales outside of the United  States and many of its <font color="blue">manufacturing</font> <font color="blue">facilities</font> and suppliers are located  outside of the US, it is subject to risks <font color="blue">generally</font> <font color="blue">associated with</font>  <font color="blue">international</font> <font color="blue">operations</font>, such as: unexpected changes in <font color="blue">regulatory</font>  <font color="blue">requirements</font>; tariffs, customs, duties and other trade barriers; difficulties in  staffing and managing foreign <font color="blue">operations</font>; differing labor <font color="blue">regulations</font>; longer  <font color="blue">payment cycles</font> and problems in collecting accounts receivable; risks arising  from a specific countryapstas or regionapstas political or <font color="blue">economic <font color="blue">conditions</font></font>,  including the <font color="blue">possibility</font> of <font color="blue">terrorist actions</font> and <font color="blue">economic destabilization</font> of a  region; destruction or <font color="blue">natural disasters</font> in <font color="blue">significant</font> geographical areas where  <font color="blue"><font color="blue">the Company</font> </font>or its suppliers have <font color="blue">manufacturing</font> <font color="blue">facilities</font>; outbreak of life  <font color="blue">threatening</font> communicable disease; <font color="blue">fluctuations</font> in currency <font color="blue">exchange rates</font>;  foreign exchange controls that restrict or prohibit <font color="blue">repatriation</font> of funds;  export and import <font color="blue">restrictions</font> or <font color="blue">prohibitions</font>; delays from customs brokers or  <font color="blue">government</font> agencies; changes in foreign medical <font color="blue">reimbursement</font> policies and  programs; differing protection of <font color="blue"><font color="blue">intellectual</font> property</font>; and <font color="blue">potentially</font> adverse  tax <font color="blue">consequences</font> resulting from operating in multiple <font color="blue"><font color="blue">jurisdiction</font>s</font> with  <font color="blue">different</font> tax laws</td>
    </tr>
    <tr>
      <td>Any one or more of these risks could materially <font color="blue">adversely</font>  impact the success of <font color="blue">the Company</font>apstas <font color="blue">international</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As <font color="blue">the Company</font>apstas  revenues from <font color="blue">international</font> <font color="blue">operations</font> increase, an increasing portion of its  revenues and expenses are being <font color="blue">denominated</font> in currencies other than US  dollars and, <font color="blue">consequently</font>, changes in <font color="blue">exchange rates</font> are having a greater effect  on its <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inventory </font><font color="blue">management</font> is a concern in <font color="blue">international</font> <font color="blue">operations</font>  due to the potential for rapidly changing business <font color="blue">conditions</font> and currency  exposure</td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">such factors will</font> not have a material  adverse effect on <font color="blue">the Company</font>apstas business, <font color="blue">financial condition</font> and results of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, there can be no assurance that laws or <font color="blue">administrative</font>  practices relating to regulation of <font color="blue">medical devices</font>, labor, taxation, foreign  exchange or other matters of <font color="blue">countries within which</font> <font color="blue"><font color="blue">the Company</font> </font>operates will  not change</td>
    </tr>
    <tr>
      <td>Any such change <font color="blue">could also</font> have a material adverse effect on the  Companyapstas business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Potential Product Liability           The Companyapstas business exposes it to potential <font color="blue">product <font color="blue">liability</font></font> risks  which are inherent in the design, <font color="blue">manufacture</font> and marketing of <font color="blue">catheters</font> and  related <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>The Companyapstas products are often used in surgical and  <font color="blue">intensive care settings with</font> <font color="blue">seriously ill patients</font></td>
    </tr>
    <tr>
      <td>In addition, many of the  <font color="blue">medical devices</font> <font color="blue">manufacture</font>d and sold by <font color="blue"><font color="blue">the Company</font> </font>are designed to be  implanted in the human body for <font color="blue">long periods</font> of time, and component failures,  <font color="blue">manufacturing</font> flaws, design defects or inadequate <font color="blue">disclosure</font> of product-related  risks <font color="blue">with respect</font> to these or other products <font color="blue">manufacture</font>d or sold by the  Company could result in an <font color="blue">unsafe condition</font> or injury to, or death of, the  patient</td>
    </tr>
    <tr>
      <td>The occurrence of such a <font color="blue">problem could</font> result in <font color="blue">product <font color="blue">liability</font></font>  claims and/or a recall of, or <font color="blue">safety alert</font> relating to, one or more of the  Companyapstas products</td>
    </tr>
    <tr>
      <td>There can be no assurance that the <font color="blue">product <font color="blue">liability</font></font>  insurance maintained by <font color="blue"><font color="blue">the Company</font> </font>will be available or sufficient to satisfy  all claims made against it or that it will be able to obtain insurance in the  future at satisfactory rates or in <font color="blue">adequate amounts</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims,  <font color="blue">safety alert</font>s or <font color="blue">product recalls</font> in the future, regardless of their ultimate  outcome, could result in <font color="blue">costly <font color="blue">litigation</font></font> and could have a material adverse  effect on <font color="blue">the Company</font>apstas business, reputation, its ability to attract and retain  customers for its products and its results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>,  physicians, hospitals and other <font color="blue">medical service providers</font> who are users of the  Companyapstas products have become subject to an increasing number of lawsuits  alleging <font color="blue">medical malpractice</font></td>
    </tr>
    <tr>
      <td>Medical <font color="blue">malpractice suits often involve</font> large  claims and substantial <font color="blue">defense costs</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is subject to the risks  <font color="blue">associated with</font> any such <font color="blue">medical malpractice</font> lawsuits</td>
    </tr>
    <tr>
      <td>Supply Interruptions           Raw materials and <font color="blue">purchased <font color="blue">components</font></font> relating to <font color="blue">the Company</font>apstas business  have <font color="blue">typically been available within</font> the <font color="blue">lead times</font> required by <font color="blue">the Company</font></td>
    </tr>
    <tr>
      <td>However, there can be no assurance that they <font color="blue">will continue</font> to be <font color="blue">available on</font>  the <font color="blue">same terms</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>maintains <font color="blue">single suppliers</font> for certain of its  out-sourced <font color="blue">components</font>, and, although it has considered and continues to explore  <font color="blue"><font color="blue">alternative</font> vendors</font> for many of these items, there can be <font color="blue">no certainty</font> that  suitable <font color="blue"><font color="blue">alternative</font> vendors</font>, if needed, could be identified</td>
    </tr>
    <tr>
      <td>Furthermore, the  Company does not typically pursue <font color="blue">regulatory</font> qualification of <font color="blue">alternative</font>  <font color="blue">sources due</font> to the strength of its <font color="blue">existing supplier <font color="blue">relationships</font></font> and the time  and expense <font color="blue">associated with</font> the <font color="blue">regulatory</font> <font color="blue">validation</font> process</td>
    </tr>
    <tr>
      <td>If the <font color="blue">Company  </font>were unable to obtain these <font color="blue">raw materials</font> or there were a <font color="blue">significant</font> increase  in the price of <font color="blue">essential materials</font> or <font color="blue">components</font>, its business could be harmed</td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>upon <font color="blue">Strong Relationships </font>with Physicians           The research, <font color="blue">development</font>, marketing and sale of many of <font color="blue">the Company</font>apstas  products is <font color="blue">dependent upon</font> <font color="blue"><font color="blue">the Company</font> </font>maintaining strong working <font color="blue">relationships</font>  <font color="blue">with physicians</font> and other <font color="blue">health care <font color="blue">professionals</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">relies on</font> these  <font color="blue">professionals</font> to provide it with considerable knowledge and experience regarding  its products and the marketing of its products</td>
    </tr>
    <tr>
      <td>(11)  <PAGE>    Physicians assist <font color="blue"><font color="blue">the Company</font> </font>as <font color="blue">researchers</font>, marketing consultants, product  consultants, inventors and <font color="blue">as public speakers</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">the Company</font> </font>fails to maintain  its working <font color="blue">relationships</font> <font color="blue">with physicians</font> and receive the benefits of their  knowledge, advice and input, many of its <font color="blue">products may</font> not be developed and  marketed in line with the needs and <font color="blue">expectations</font> of the <font color="blue">professionals</font> who use  and support its products, which could have a material adverse effect on its  business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Associated </font>with Derivative Financial Instruments           As a partial hedge against adverse <font color="blue">fluctuations</font> in <font color="blue">exchange rates</font>, the  Company <font color="blue">periodically</font> enters into foreign currency exchange contracts with  <font color="blue">certain major financial institutions</font></td>
    </tr>
    <tr>
      <td>By their nature, all <font color="blue">such contracts</font>  <font color="blue">involve risk</font>, including the risk of <font color="blue">nonperformance by counterparties</font></td>
    </tr>
    <tr>
      <td>Accordingly, losses relating to these <font color="blue">contracts could</font> have a material adverse  effect upon <font color="blue">the Company</font>apstas business, <font color="blue">financial condition</font> and results of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Companyapstas Foreign Currency Management Policy prohibits the use  of <font color="blue">derivative instruments</font> for <font color="blue">speculative purposes</font></td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>on Key Management           The Companyapstas <font color="blue">success depends upon</font> the <font color="blue">continued contributions</font> of key  members of its senior <font color="blue">management</font> team</td>
    </tr>
    <tr>
      <td>Accordingly, loss of the services of one  or more of these key members of <font color="blue">management</font> could have a material adverse effect  on <font color="blue">the Company</font>apstas business</td>
    </tr>
    <tr>
      <td>None of these <font color="blue">individuals</font> has an <font color="blue">employment</font> <font color="blue">agreement</font>  with <font color="blue">the Company</font></td>
    </tr>
  </tbody>
</table>